SLXP

Salix Pharmaceuticals Announces 4Q2012 And Fy2012 Financial Results Conference Call And Webcast

[at noodls] – RALEIGH, NC, February 14, 2013 – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter and full year 2012 financial results following the close of the U.S. … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboardSee who Salix is hiring next, click here to […]

Salix Pharmaceuticals To Present At Two Investment Conferences In March

[at noodls] – RALEIGH, NC, February 25, 2013 – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two investment conferences during March 2013. Information regarding these conferences … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboardSee who Salix is hiring next, click here to view […]

Salix Pharmaceuticals Reports 4Q2012 And FY2012 Results

[at noodls] – 36% Increase in Full Year Product Revenue 24% Increase in Full Year XIFAXAN® Prescriptions on a Milligram Basis 29% Increase in Full Year APRISO® Prescriptions 137% Increase in Full Year RELISTOR® Prescriptions … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboardSee who Salix is hiring next, click here […]

Salix Pharmaceuticals To Present At Two Investment Conferences In March

[at noodls] – RALEIGH, NC, March 25, 2013 – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two investment conferences during March 2013. Information regarding these conferences … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboardSee who Salix is hiring next, click here to view […]

Salix Pharmaceuticals Announces 4Q2012 And Fy2012 Financial Results Conference Call And Webcast

[at noodls] – RALEIGH, NC, February 14, 2013 – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter and full year 2012 financial results following the close of the U.S. … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboardSee who Salix is hiring next, click here to […]

FDA Approves Fulyzaqâ„¢ (Crofelemer) 125 mg Delayed-Release Tablets For The Symptomatic Relief Of Diarrhea In Patients With HIV/AIDS On Anti-Retroviral Therapy (ART)

[at noodls] – Fulyzaqâ„¢ Offers a Unique Treatment for ART-Related Diarrhea in HIV Positive Patients RALEIGH, NC, January 2, 2013 – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboardSee who Salix is hiring next, click here to view […]

Salix Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

[at noodls] – RALEIGH, NC, January 2, 2013 Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of the presentation will be available at the same location….This … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboardSee who Salix is hiring next, click here to […]

PHOTOCURE ANNOUNCES PAYMENT RECEIVED FOR LUMACAN® DEVELOPMENT

[at noodls] – Oslo, Norway, January 2, 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that it has received a payment … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboardSee who Salix is hiring next, click here to view […]

PropThink: Positive Naloxegol Results; NKTR Powering Through Analyst Downgrade

[ACN Newswire] – By David MoskowitzNektar Therapeutics (NASDAQ:NKTR) hosted a conference call Monday morning, highlighting the successful results from two Phase III trials and one safety extension study for Naloxegol, … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboard […]

Salix Pharmaceuticals Reports 3Q2012 Results

[at noodls] – Management Maintains 2012 Revenue Guidance of $735 Million And Increases Guidance for Adjusted Net Income to $200 Million or $3.13, Per Share, Fully Diluted 27% Increase in Year-over-Year 3Q Product Revenue … moreView todays social media effects on SLXPView the latest stocks trending across Twitter. Click to view dashboard […]